Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Levofloxacin on the Efficacy and Adverse Events in Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer: Results of a Randomized, Prospective, Multicenter Study.
Numakura K, Kobayashi M, Ishida T, Okane K, Suzuki K, Shimoda N, Suzuki T, Kumazawa T, Sasaki R, Fukuda H, Kashima S, Yamamoto R, Koizumi A, Nara T, Kanda S, Huang M, Saito M, Narita S, Inoue T, Tsuchiya N, Habuchi T. Numakura K, et al. Among authors: ishida t. Eur Urol Focus. 2022 Nov;8(6):1666-1672. doi: 10.1016/j.euf.2022.06.002. Epub 2022 Jun 15. Eur Urol Focus. 2022. PMID: 35717522 Clinical Trial.
Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.
Muto Y, Narita S, Hatakeyama S, Maita S, Chiba S, Kubo K, Aoyama Y, Ito R, Takahashi Y, Takahashi S, Nakamura K, Honma N, Sato H, Koizumi A, Igarashi R, Okane K, Ishida T, Horikawa Y, Kumazawa T, Akihama S, Shimoda J, Suzuki T, Ohyama C, Habuchi T. Muto Y, et al. Among authors: ishida t. Med Oncol. 2021 Mar 13;38(4):37. doi: 10.1007/s12032-021-01480-3. Med Oncol. 2021. PMID: 33713196
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Nomura K, Habuchi T. Narita S, et al. Among authors: ishida t. World J Urol. 2022 May;40(5):1135-1141. doi: 10.1007/s00345-022-03963-y. Epub 2022 Feb 26. World J Urol. 2022. PMID: 35218371
Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.
Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Habuchi T. Narita S, et al. Among authors: ishida t. Int J Clin Oncol. 2022 Sep;27(9):1477-1486. doi: 10.1007/s10147-022-02203-y. Epub 2022 Jun 24. Int J Clin Oncol. 2022. PMID: 35748967
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Kobayashi M, Numakura K, Hatakeyama S, Ishida T, Koizumi A, Tadachi K, Igarashi R, Takayama K, Muto Y, Sekine Y, Sobu R, Sasagawa H, Akashi H, Kashima S, Yamamoto R, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Kobayashi M, et al. Among authors: ishida t. Int J Clin Oncol. 2023 Nov;28(11):1530-1537. doi: 10.1007/s10147-023-02394-y. Epub 2023 Aug 8. Int J Clin Oncol. 2023. PMID: 37552353
4,815 results